Israeli pharmaceutical company Protalix BioTherapeutics has announced initial positive results from its Phase I clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), in patients with Gaucher disease. In the trial, oral ...
Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. Uplyso, referred to as Elelyso (taliglucerase alfa) ...
Tags: Pfizer, Protalix, Protalix BioTherapeutics
Israel-based Protalix BioTherapeutics has signed an agreement with Pfizer to continue managing the development activities of Gaucher disease drug Elelyso. According to the clinical development agreement, Protalix will continue to manage ...
Tags: Protalix, Pfizer, Gaucher disease drug
Biopharmaceutical company Protalix BioTherapeutics has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical trials of PRX-102. The Company is planning to ...
Tags: Protalix BioTherapeutics, investigational new drug, IND, PRX-102
Pfizer and Protalix BioTherapeutics have announced FDA approval of Elelyso (taliglucerase alfa) for injection to treat type 1 Gaucher disease. Elelyso, derived from ProCellEx, is an enzyme replacement therapy (ERT) for the long-term ...
Tags: Protalix/Pfizer Gaucher Drug, Pfizer and Protalix BioTherapeutics